We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Offers products in medical imaging - diagnostic imaging, contrast media - contrast agents, MRI imaging, X Ray imaging... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Guerbet and Bracco Enter Into Global Collaboration for Next-Generation MRI Contrast Agent Gadopiclenol

By MedImaging International staff writers
Posted on 15 Dec 2021
Print article

Guerbet (Paris, France) and Bracco Imaging S.p.A. (Milan, Italy) have signed a global collaboration for Gadopiclenol, a next-generation magnetic resonance imaging (MRI) contrast agent, that will result in the companies commercializing the product independently under different brand names. The companies will also collaborate on manufacturing, as well as research and development for future indications.

A next-generation, macrocyclic gadolinium-based contrast agent with high relaxivity, Gadopiclenol is intended to improve lesion detection and visualization in MRI scanning, with lower doses of gadolinium compared to other agents already on the market. In March 2021, positive results from two Phase III studies comparing the diagnostic efficacy and safety of Gadopiclenol, which uses half the dose of gadolinium compared to Gadobutrol, in a wide range of indications, covering the central nervous system and various other anatomical areas (head and neck, thorax, breast, abdomen, pelvis, musculoskeletal system) were published by Guerbet. Both Guerbet and Bracco each own valuable intellectual property relating to Gadopiclenol.

Guerbet will manufacture Gadopiclenol active ingredient and vials for Bracco for up to seven years. Following a technology transfer, both companies will have the ability to manufacture the product. The first marketing authorizations are anticipated in 2023, initially in the US and the European Union (EU), with other geographies to follow.

"Gadopiclenol will be an excellent extension of Guerbet's UNIK MRI solutions of contrast media, injectors, consumables, services and software. It will enable our customers to use a lower dose of gadolinium in their everyday clinical practice. Our ambition is to make this available to as many patients as soon as possible. This is a bold decision which will accelerate our ability to further develop Gadopiclenol, which will bring significant health benefits worldwide," said CEO of Guerbet, David Hale

"Gadopiclenol represents real and valuable innovation in MRI, with a unique profile of stability and contrast enhancement properties that will allow a low dose to be effectively used in a large number of clinical settings and clinical indications," said CEO of Bracco Imaging, Fulvio Renoldi Bracco. "We are excited about this strategic addition to Bracco Imaging's MRI portfolio. Once approved, the addition of Gadopiclenol will expand our portfolio to include three different products that will help to shape the future of prevention and precision diagnostic imaging, in accordance with our global strategy."

Related Links:
Bracco Imaging S.p.A. 

Print article



view channel
Image: Spinal fractures in the elderly are preventable with simple X-rays (Photo courtesy of Pexels)

Simple X-Ray Method Can Diagnose Vertebral Compression and Prevent Spinal Fractures

Vertebral compression means that the spine is compressed, causing a fracture in one of the vertebrae. Vertebral compression fractures (VCFs) occur easily in people with osteoporosis and are very common... Read more

Imaging IT

view channel

Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology

The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.